SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jon Koplik who wrote (1481)2/10/1999 11:41:00 PM
From: scaram(o)uche  Read Replies (3) of 2135
 
Sundeen noted that in 1996, Bristol-Myers quit research into using the
controversial drug Thalidomide to help cancer patients. EntreMed went ahead
and developed the product and licensed it to Celgene Inc., which received
FDA approval last year and has seen strong early sales.

Now, that's spin. That's spin ART.

Do you suppose it came from Sundeen that way, or that the reporter put it together that way?

If it came from Sundeen that way...... tweeeeeeeeet! foul! penalty of $1/share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News